CXL can be used to treat infectious fungal keratitis

Article

Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani.

Corneal cross-linking (CXL) is effective in reducing the severity of infectious keratitis caused by Fusarium solani, according to a study in the Journal of Cornea and External Disease.

Dr Gustavo Galperin, Laboratorio de Investigaciones Oculares, Buenos Aires, Argentina, led an investigation on 24 rabbits innoculated with Fusarium solani in the stromata of the right cornea.

All rabbits were divided into two groups. Group 1 was treated with CXL 72 hours after inoculation and group 2, acting as control, received no treatment. In both groups all eyes were assessed preoperatively on days 0 and 3, and postoperatively on day 7. Eyes were enucleated and the corneal buttons were microbiologically and histologically examined.

Clinical scores were statistically significant between the two groups after CXL, with group 1 demonstrating a significantly lower clinical score. Group 1 had 22.45 ± 5.09 CFU/g compared with 42.5 ± 3.12 CFU/g in group 2.

Similar amounts of Fusarium hyphae and inflammatory cells were found in 3 corneal buttons from group 2. In 2 of the 3 buttons obtained from group 1 there were fewer Fusarium hyphae, inflammatory cells, and nonspecific stromal changes than in group 2.

The study results suggest that CXL could be helpful as a coadjuvant for the treatment of resistant fungal infections.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.